Xvivo Perfusion AB (OSTO:XVIVO) Retained Earnings

: kr119.6 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Xvivo Perfusion AB's retained earnings for the quarter that ended in Dec. 2023 was kr119.6 Mil.

Xvivo Perfusion AB's quarterly retained earnings increased from Jun. 2023 (kr48.8 Mil) to Sep. 2023 (kr51.1 Mil) and increased from Sep. 2023 (kr51.1 Mil) to Dec. 2023 (kr119.6 Mil).

Xvivo Perfusion AB's annual retained earnings increased from Dec. 2021 (kr9.3 Mil) to Dec. 2022 (kr27.8 Mil) and increased from Dec. 2022 (kr27.8 Mil) to Dec. 2023 (kr119.6 Mil).

Xvivo Perfusion AB Retained Earnings Historical Data

The historical data trend for Xvivo Perfusion AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

44.86

1.13

9.28

27.75

119.57

Xvivo Perfusion AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															27.75	41.62	48.82	51.10	119.57

Xvivo Perfusion AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Xvivo Perfusion AB (OSTO:XVIVO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Xvivo Perfusion AB (OSTO:XVIVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OSTO:XVIVO) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

XVIPF:USA 3XV:Germany

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (OSTO:XVIVO) Headlines

No Headlines